Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Dermatologikum Hamburg · Probity Medical Research · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
555
total citations
- FWCI
- 27.37
- Percentile
- 100%
- References
- 47
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Medicine
- Etanercept
- Placebo
- Psoriasis
- Internal medicine
- Psoriasis Area and Severity Index
- Clinical trial
- Dermatology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.